XERISOL
Live / Applied — Second extension granted (statement of use) (as of 26 Dec 2025)
What this means for you
Not registered yet, but its 01 Aug 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98677670
- Mark type
- Stylized text
- Filed
- 01 Aug 2024
- Published for opposition
- 26 Nov 2024
- Attorney of record
- Tracy-Gene G. Durkin
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of diseases and conditions, namely, alimentary tract, metabolic, oncologic, autoimmune, and nervous system diseases and conditions; pharmaceutical preparations for the treatment of diseases and conditions, namely, anti-invectives to prevent or treat infections, vaccines, antineoplastic pharmaceutical preparations for the treatment of cancer, and immunomodulating pharmaceutical preparations for the treatment of immune system related diseases and disorders
Owner
- Xeris Pharmaceuticals, Inc., Chicago, IL, US
- Xeris Pharmaceuticals, Inc., Chicago, IL, US
Prosecution history
- 27 Dec 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 26 Dec 2025 — SOU EXTENSION 2 GRANTED
- 26 Dec 2025 — SOU EXTENSION 2 FILED
- 26 Dec 2025 — SOU TEAS EXTENSION RECEIVED
- 08 Jul 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 07 Jul 2025 — SOU EXTENSION 1 GRANTED
- 07 Jul 2025 — SOU EXTENSION 1 FILED
- 07 Jul 2025 — SOU TEAS EXTENSION RECEIVED
- 07 Jan 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 26 Nov 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 26 Nov 2024 — PUBLISHED FOR OPPOSITION
- 20 Nov 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 02 Nov 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 02 Nov 2024 — ASSIGNED TO EXAMINER
- 01 Aug 2024 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED